Yaoming biology and Bayer reach an acquisition agreement on a biological preparation factory in Germany

January 16, 2020 / AP / -- the world's leading open biopharmaceutical technology platform company, Yaoming bio, and Bayer today jointly announced an agreement to take over the operation of Bayer's biopharmaceutical plant in Leverkusen, Germany, purchase relevant equipment, and a long-term lease contract attached to the plant According to the production cooperation agreement under negotiation, the plant will be operated by yaomingbio and serve as an auxiliary production service provider of Bayer company's product keyuech ® (recombinant anti hemophilia factor) On the basis of meeting the customary closing conditions, the transaction is planned to be completed in the next few months, and the relevant financial details are not disclosed "We are pleased to sign an acquisition agreement with Bayer to further improve the company's production capacity of high-quality preparations." Dr Chen Zhisheng, CEO of YaoMing bio, said, "in recent years, the business of YaoMing bio in the three markets of EU, US and China has maintained a rapid growth, and this acquisition further demonstrates the company's continued practice of the strategy of" providing global two plant production by Yaoming bio " Yaoming biology will continue to expand its biopharmaceutical production capacity, provide high-quality biopharmaceuticals to customers through the company's sound and strong global supply chain network, and benefit patients " Adorable adorable